Although the arguments about access to drugs through parallel imports and compulsory-licensing agreements may have some theoretical validity, the disincentive to investment provided by such measures is massive.

ECONOMIST: Homeward bound?

The current RFIs take that process another step, seeking further guidance on access to scientific publications and initiating a parallel process relating to digital data, as called for in the COMPETES Act.

WHITEHOUSE: Request for Information on Public Access to Digital Data and Scientific Publications | The White House